SLUG transcription factor : a pro-survival and prognostic factor in gastrointestinal stromal tumour

Show full item record



Permalink

http://hdl.handle.net/10138/229599

Citation

Pulkka , O-P , Nilsson , B , Sarlomo-Rikala , M , Reichardt , P , Eriksson , M , Hall , K S , Wardelmann , E , Vehtari , A , Joensuu , H & Sihto , H 2017 , ' SLUG transcription factor : a pro-survival and prognostic factor in gastrointestinal stromal tumour ' , British Journal of Cancer , vol. 116 , no. 9 , pp. 1195-1202 . https://doi.org/10.1038/bjc.2017.82

Title: SLUG transcription factor : a pro-survival and prognostic factor in gastrointestinal stromal tumour
Author: Pulkka, Olli-Pekka; Nilsson, Bengt; Sarlomo-Rikala, Maarit; Reichardt, Peter; Eriksson, Mikael; Hall, Kirsten Sundby; Wardelmann, Eva; Vehtari, Aki; Joensuu, Heikki; Sihto, Harri
Contributor: University of Helsinki, Clinicum
University of Helsinki, HUSLAB
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2017-04
Language: eng
Number of pages: 8
Belongs to series: British Journal of Cancer
ISSN: 0007-0920
URI: http://hdl.handle.net/10138/229599
Abstract: Background: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown. Methods: Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and adjuvant imatinib. Results: SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both when patients were treated with surgery alone (HR = 3.40, 95% CI = 1.67-6.89, P = 0.001) and when treated with surgery plus adjuvant imatinib (HR = 1.83, 95% CI = 1.29-2.60, P = 0.001). Conclusions: GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling in GISTs.
Subject: gastrointestinal stromal tumour
SLUG
SNAI2
survival
proliferation
apoptosis
C-KIT
ADJUVANT IMATINIB
P53-MEDIATED APOPTOSIS
CISPLATIN RESISTANCE
SIGNALING PATHWAY
RANDOMIZED-TRIAL
OVARIAN-CANCER
MUTATIONS
MESYLATE
SNAIL
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
bjc201782a.pdf 850.2Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record